Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

October 20, 2006 09:00 ET

Holmes Biopharma-Omaha Commences Work on First Contract

SCOTTSDALE, ARIZONA--(CCNMatthews - Oct. 20, 2006) - Holmes Biopharma, Inc. (OTCBB:HLMB) announced today that its Clinical Pharmacology Division in Omaha, Nebraska, has commenced work on its first contract, a Phase 1 trial for rheumatoid arthritis patients.

The initial work includes an extensive marketing initiative to build a database of study participants for current and future studies. In parallel to these marketing efforts, the company is expanding its physician network for referral of qualified patients in upcoming trials.

Qualia's state of the art call center has completed the preliminary screening for this study, and the recruiting team has facilitated the screening of patients including, informed consent, medical history, height/weight, vital signs, blood pressure, ECG, urine collection and blood draws.

"The efforts of the recruiting team have shown the commitment to quality we have. We are now on a successful path of implementing patient and healthy volunteer trials. Not just saying it, but getting it done," said Jim Cunningham, Recruiting Director located in Omaha, Nebraska.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information